Showing results (61-70 of 151) with videos related to
Sort By:
Pageof 16
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 25, 2023
Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)Helen Hanson, Esteban Astiazaran-Symonds, Laura M Amendola, et al.Genes|September 28, 2021
Investigation and Management of Apparently Sporadic Central Nervous System Haemangioblastoma for Evidence of Von Hippel-Lindau DiseaseHugh Furness, Louay Salfity, Johanna Devereux, et al.Journal of Medical Genetics|November 19, 2020
Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendationsAlice Garrett, Miranda Durkie, Alison Callaway, et al.The Lancet. Oncology|May 13, 2023
Utility of polygenic risk scores in UK cancer screening: a modelling analysisCatherine Huntley, Bethany Torr, Amit Sud, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.European Urology Oncology|December 14, 2019
Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected IndividualsClaire Forde, Derek H K Lim, Yousef Alwan, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 3, 2024
Classification of variants of reduced penetrance in high-penetrance cancer susceptibility genes: Framework for genetics clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group-UK)Alice Garrett, Sophie Allen, Miranda Durkie, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.Journal of Genetic Counseling|August 7, 2025
Optimizing risk-reducing surgery and aspirin decision aids for Lynch syndrome carriers using the person-based approach: A think-aloud interview studyKelly Kohut, Kate Morton, Lesley Turner, et al.British Journal of Haematology|February 6, 2023
Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working GroupBeverley Speight, Helen Hanson, Clare Turnbull, et al.Pageof 16